ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...
Chemoimmunotherapy extended PFS compared with chemotherapy for patients with extensive-stage small cell lung cancer and ECOG performance status of 2 or 3, according to retrospective study results. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback